What to Eat on GLP-1 Medications Like Ozempic and Wegovy (Full Guide)

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most significant shift in obesity and metabolic medicine in a generation. In the STEP 1 trial, semaglutide produced a mean weight loss of 14.9% over 68 weeks (Wilding et al., NEJM 2021); SURMOUNT-1 showed up to 20.9% with tirzepatide (Jastreboff et al., NEJM 2022). But the medication only does half the work — what you eat on a GLP-1 determines whether the weight you lose is fat or muscle, and whether the results last after you stop.

The three nutrition risks no one warns you about

• Lean mass loss: DEXA sub-studies of STEP 1 found that roughly 25–40% of weight lost on semaglutide came from lean mass when protein intake and resistance training were inadequate (Wilding et al., Diabetes Obes Metab 2021).
• Micronutrient gaps: smaller meals mean less iron, B12, calcium, and fiber unless you're intentional — particularly relevant given documented dose-dependent reductions in total caloric intake.
• Rebound weight gain: in the STEP 1 extension trial, participants regained two-thirds of lost weight within a year of stopping semaglutide (Wilding et al., Diabetes Obes Metab 2022). Muscle is your metabolic engine — losing it lowers resting metabolism and makes regain easier.

The daily framework

1. Anchor every meal in protein

Aim for 1.2–1.6 g of protein per kg of body weight per day during active weight loss — the range supported by ISSN position statements (Jäger et al., JISSN 2017) and replicated in obesity-treatment trials for muscle preservation. Front-load earlier when appetite is highest. Practically, that's 30–40 g of protein at breakfast, lunch, and dinner. Greek yogurt, eggs, cottage cheese, chicken, fish, tofu, tempeh, and lean beef are the workhorses. A protein shake counts when food won't fit.

2. Don't skip fiber — it prevents the GI side effects

Constipation, bloating, and nausea are the most common reasons people stop GLP-1s (Wharton et al., Postgrad Med 2022). Soluble fiber from oats, chia, beans, berries, kiwi, and psyllium softens stools and feeds the gut microbiome. Target 25–35 g per day (Institute of Medicine DRI), increased gradually with plenty of water.

3. Eat color and healthy fats for micronutrient density

Half your plate should be non-starchy vegetables. Add olive oil, avocado, nuts, and fatty fish for absorption of fat-soluble vitamins (A, D, E, K). When meals are smaller, density matters more than volume.

4. Hydrate like it's part of the prescription

Reduced thirst is a quiet side effect. Aim for half your body weight in ounces of water, more if you're active. Electrolytes help on lower-carb days.

A sample day on a GLP-1

• Breakfast: Greek yogurt parfait with berries, chia seeds, and walnuts (35 g protein, 9 g fiber)
• Lunch: Grilled chicken bowl with quinoa, roasted vegetables, avocado, olive oil (40 g protein)
• Snack: Cottage cheese with kiwi or a high-protein shake
• Dinner: Salmon, lentils, sautéed greens with garlic and lemon (35 g protein, omega-3s, fiber)

Lift heavy things, two to three times per week

Resistance training is non-negotiable on a GLP-1. A 2024 trial in NEJM (Lundgren et al.) found that combining semaglutide with supervised exercise preserved lean mass and improved cardiorespiratory fitness in ways the drug alone did not. Two to three sessions per week of compound movements (squats, presses, rows, hinges) is enough to dramatically reduce lean mass loss.

What we still don't know — and how to plan for it

The long-term (5+ year) data on GLP-1s in non-diabetic weight management is still maturing. What is clear from STEP and SURMOUNT is that most weight is regained within a year of discontinuation if eating patterns and resistance training haven't been rebuilt (Wilding et al., 2022). Plan from day one as if the medication is scaffolding, not a permanent floor — protein, lifting, fiber, and sleep are the structures that hold up after the scaffolding comes down.

A note on hydration, electrolytes, and the kidneys

Rapid weight loss and reduced fluid intake can transiently raise creatinine and stress the kidneys. A pharmacovigilance signal for acute kidney injury during GLP-1 initiation, primarily mediated by dehydration from nausea/vomiting, has been replicated across FDA AERS analyses (Filippatos et al., Expert Opin Drug Saf 2014). People with CKD should have eGFR and electrolytes monitored more often during titration, and should avoid combining GLP-1s with NSAIDs or dehydration without clinician input.